New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
CMOs showed an increasing reluctance to take on debt in 2022
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
Subscribe To Our Newsletter & Stay Updated
